HF
AURA icon

HRT Financial’s Aura Biosciences AURA Stock Holding History

HRT Financial’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-56,529
Closed -$353K – 2844
2025
Q2 		$353K Buy
+56,529
New +$331K ﹤0.01% 1771

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

HRT Financial's AURA Position: Q3 2025 in Review

HRT Financial sold out of Aura Biosciences (AURA) in Q3 2025, closing a stake of 56,529 shares — an estimated $353K sold.

HRT Financial first reported a position in AURA in Q2 2025 and held it in 1 quarter. The position peaked at $353K in Q2 2025. 106 funds tracked by Wall St. Rank hold AURA as of Q3 2025.

  • HRT Financial reported no remaining Aura Biosciences position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 56,529 Aura Biosciences shares in Q3 2025, an estimated $353K.
  • HRT Financial first reported a position in Aura Biosciences in Q2 2025 and held it in 1 quarter.
  • HRT Financial's Aura Biosciences position peaked at $353K in Q2 2025.
  • 106 funds tracked by Wall St. Rank held Aura Biosciences as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.